Identification
- Generic Name
- MultiStem
- DrugBank Accession Number
- DB15742
- Background
MultiStem is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs). Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hematopoietically adherent. They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic. Additional benefits of MultiStem include their low immunogenicity, meaning they can be administered without tissue matching or concurrent immunosuppressive agents. The cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time. Currently, MultiStem is being investigated against neurological, inflammatory, immune, and cardiovascular diseases and conditions.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Cell transplant therapies
Other cell transplant therapies - Synonyms
- Multipotent Adult Progenitor Cells (MAPCs)
- External IDs
- MultiStem
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
MultiStem’s main focus is immunological, with MAPCs mainly acting by producing factors regulating the immune system, protecting damaged and injured cells, and also promoting tissue repair and healing. The MAPCs in MultiStem have the ability to express a range of therapeutically relevant proteins and factors with the potential to reduce inflammation, protect damaged or injured tissue, and enhance the formation of new blood vessels in areas of ischemic injury. Immune-wise, it acts to rebalance the immune system, with studies by the company showing that the therapy acts by reducing inflammation (with reduced inflammatory cytokine levels) and lessening activation and migration of the peripheral immune system to the site of injury. Additionally, this therapy potentially may have therapeutic effects through decreasing activation of the peripheral immune response to the initial injury which then results in reduction of inflammation and thereby means less secondary tissue damage and scarring while also allowing for accelerated repair processes. These cells have also been shown to lessen adverse results of inflammation while reparative immune cells are activated. In summary, there occurs simultaneous upregulation of reparative immune responses and downregulation of proinflammatory processes.
Outside of immunological applications, MAPCs are also being investigated for ischemic injury treatment and cardiovascular repair. Compared to MSCs, MAPCs have a stronger angiogenic protein release profile while also inducing more extensively developed vasculature in a study. Additionally, MAPCs also hold potential in being a functional cell source for orthopedic applications and to also promote tissue regeneration and healing. Evidence exists that MAPCs can differentiate into cells of mesenchymal lineages which includes bones, bone marrow, cartilage, fat, muscles, and tendon -- giving reason behind the investigating of MAPCs for treatment of bone and cartilage disease. MAPCs, compared to MSCs, also seem to have greater inclination for endothelial differentiation.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WNR9FH307P
- CAS number
- Not Available
References
- General References
- Khan RS, Newsome PN: A Comparison of Phenotypic and Functional Properties of Mesenchymal Stromal Cells and Multipotent Adult Progenitor Cells. Front Immunol. 2019 Aug 28;10:1952. doi: 10.3389/fimmu.2019.01952. eCollection 2019. [Article]
- LoGuidice A, Houlihan A, Deans R: Multipotent adult progenitor cells on an allograft scaffold facilitate the bone repair process. J Tissue Eng. 2016 Jul 8;7:2041731416656148. doi: 10.1177/2041731416656148. eCollection 2016 Jan-Dec. [Article]
- MultiStem [Link]
- Mechanisms of Action [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Ischemic Stroke 1 2 Completed Treatment Ischemic Stroke 1 2 Completed Treatment Ulcerative Colitis 1 2 Recruiting Treatment Adult Stem Cells / Trauma 1 2 Terminated Treatment Myocardial Infarction / Non ST Segment Elevation Myocardial Infarction (NSTEMI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at August 11, 2020 21:11 / Updated at August 13, 2020 07:02